JP2007511547A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007511547A5 JP2007511547A5 JP2006540170A JP2006540170A JP2007511547A5 JP 2007511547 A5 JP2007511547 A5 JP 2007511547A5 JP 2006540170 A JP2006540170 A JP 2006540170A JP 2006540170 A JP2006540170 A JP 2006540170A JP 2007511547 A5 JP2007511547 A5 JP 2007511547A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide fragment
- protein
- bcl
- vaccine composition
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000007079 Peptide Fragments Human genes 0.000 claims 55
- 108010033276 Peptide Fragments Proteins 0.000 claims 55
- 239000000203 mixture Substances 0.000 claims 34
- 108090000623 proteins and genes Proteins 0.000 claims 32
- 102000004169 proteins and genes Human genes 0.000 claims 32
- 229960005486 vaccine Drugs 0.000 claims 30
- 206010028980 Neoplasm Diseases 0.000 claims 22
- 201000011510 cancer Diseases 0.000 claims 18
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 claims 17
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 claims 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 210000001744 T-lymphocyte Anatomy 0.000 claims 7
- 210000000265 leukocyte Anatomy 0.000 claims 7
- 238000011282 treatment Methods 0.000 claims 7
- 239000002671 adjuvant Substances 0.000 claims 5
- 230000002163 immunogen Effects 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 210000001519 tissue Anatomy 0.000 claims 5
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims 4
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 claims 4
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 claims 4
- 125000000539 amino acid group Chemical group 0.000 claims 4
- 108700000711 bcl-X Proteins 0.000 claims 4
- 102000055104 bcl-X Human genes 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 239000013598 vector Substances 0.000 claims 4
- 102000043129 MHC class I family Human genes 0.000 claims 3
- 108091054437 MHC class I family Proteins 0.000 claims 3
- 108091008874 T cell receptors Proteins 0.000 claims 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 230000028993 immune response Effects 0.000 claims 3
- 238000011065 in-situ storage Methods 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 102100021590 Bcl-2-like protein 10 Human genes 0.000 claims 2
- 101710121492 Bcl-2-like protein 10 Proteins 0.000 claims 2
- -1 Bcl-w Proteins 0.000 claims 2
- 101150017888 Bcl2 gene Proteins 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 238000009007 Diagnostic Kit Methods 0.000 claims 2
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 claims 2
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims 2
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims 2
- 108010058607 HLA-B Antigens Proteins 0.000 claims 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 2
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims 2
- 102100037850 Interferon gamma Human genes 0.000 claims 2
- 108010074328 Interferon-gamma Proteins 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 210000004443 dendritic cell Anatomy 0.000 claims 2
- 230000009033 hematopoietic malignancy Effects 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 231100001143 noxa Toxicity 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108700028369 Alleles Proteins 0.000 claims 1
- 108020000946 Bacterial DNA Proteins 0.000 claims 1
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 claims 1
- 102100027522 Baculoviral IAP repeat-containing protein 7 Human genes 0.000 claims 1
- 102000051485 Bcl-2 family Human genes 0.000 claims 1
- 108700038897 Bcl-2 family Proteins 0.000 claims 1
- 108010084313 CD58 Antigens Proteins 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 238000011510 Elispot assay Methods 0.000 claims 1
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 claims 1
- 108010035452 HLA-A1 Antigen Proteins 0.000 claims 1
- 108010036972 HLA-A11 Antigen Proteins 0.000 claims 1
- 108010013476 HLA-A24 Antigen Proteins 0.000 claims 1
- 108010086377 HLA-A3 Antigen Proteins 0.000 claims 1
- 108010021736 HLA-B15 Antigen Proteins 0.000 claims 1
- 108010061486 HLA-B27 Antigen Proteins 0.000 claims 1
- 102000012153 HLA-B27 Antigen Human genes 0.000 claims 1
- 108010004141 HLA-B35 Antigen Proteins 0.000 claims 1
- 108010014597 HLA-B44 Antigen Proteins 0.000 claims 1
- 108010075326 HLA-B51 Antigen Proteins 0.000 claims 1
- 108010091938 HLA-B7 Antigen Proteins 0.000 claims 1
- 108010039075 HLA-B8 Antigen Proteins 0.000 claims 1
- 101000936083 Homo sapiens Baculoviral IAP repeat-containing protein 7 Proteins 0.000 claims 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 1
- 108090000144 Human Proteins Proteins 0.000 claims 1
- 102000003839 Human Proteins Human genes 0.000 claims 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 claims 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims 1
- 108091093037 Peptide nucleic acid Proteins 0.000 claims 1
- 108010002687 Survivin Proteins 0.000 claims 1
- 230000024932 T cell mediated immunity Effects 0.000 claims 1
- 238000007792 addition Methods 0.000 claims 1
- 230000002424 anti-apoptotic effect Effects 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 210000000601 blood cell Anatomy 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 210000003162 effector t lymphocyte Anatomy 0.000 claims 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 238000000159 protein binding assay Methods 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52311903P | 2003-11-19 | 2003-11-19 | |
| US60/523,119 | 2003-11-19 | ||
| DKPA200301716 | 2003-11-19 | ||
| DKPA200301716 | 2003-11-19 | ||
| PCT/DK2004/000799 WO2005049073A2 (en) | 2003-11-19 | 2004-11-18 | Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011198605A Division JP5502823B2 (ja) | 2003-11-19 | 2011-09-12 | Ｂｃｌ−２ファミリ−に属するタンパク質およびそのフラグメント、ならびに癌患者におけるそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007511547A JP2007511547A (ja) | 2007-05-10 |
| JP2007511547A5 true JP2007511547A5 (enExample) | 2007-12-27 |
| JP4926714B2 JP4926714B2 (ja) | 2012-05-09 |
Family
ID=39149116
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006540170A Expired - Lifetime JP4926714B2 (ja) | 2003-11-19 | 2004-11-18 | Ｂｃｌ−２ファミリ−に属するタンパク質およびそのフラグメント、ならびに癌患者におけるそれらの使用 |
| JP2011198605A Expired - Lifetime JP5502823B2 (ja) | 2003-11-19 | 2011-09-12 | Ｂｃｌ−２ファミリ−に属するタンパク質およびそのフラグメント、ならびに癌患者におけるそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011198605A Expired - Lifetime JP5502823B2 (ja) | 2003-11-19 | 2011-09-12 | Ｂｃｌ−２ファミリ−に属するタンパク質およびそのフラグメント、ならびに癌患者におけるそれらの使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7842294B2 (enExample) |
| EP (2) | EP1691824B1 (enExample) |
| JP (2) | JP4926714B2 (enExample) |
| KR (2) | KR101216655B1 (enExample) |
| CN (1) | CN1921878B (enExample) |
| AT (1) | ATE424842T1 (enExample) |
| AU (1) | AU2004290866B2 (enExample) |
| CA (1) | CA2546794C (enExample) |
| DE (1) | DE602004019965D1 (enExample) |
| DK (2) | DK1691824T3 (enExample) |
| ES (2) | ES2323588T3 (enExample) |
| MX (1) | MXPA06005738A (enExample) |
| PL (2) | PL1691824T3 (enExample) |
| PT (1) | PT1691824E (enExample) |
| RU (1) | RU2367468C2 (enExample) |
| WO (1) | WO2005049073A2 (enExample) |
| ZA (1) | ZA200604866B (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7892559B2 (en) * | 2002-01-30 | 2011-02-22 | Survac Aps | Survivin-derived peptides and use thereof |
| PT2359841E (pt) * | 2003-01-30 | 2015-02-10 | Survac Aps | Péptidos derivados de survivina e a sua utilização |
| US7612162B2 (en) | 2004-09-21 | 2009-11-03 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response |
| CA2584990A1 (en) * | 2004-10-19 | 2006-04-27 | Massachusetts Institute Of Technology | Virus scaffold for self-assembled, flexible and light lithium battery |
| AU2011203535B2 (en) * | 2005-02-04 | 2012-10-11 | Survac Aps | Survivin peptide vaccine |
| ES2523172T3 (es) * | 2005-02-04 | 2014-11-21 | Survac Aps | Vacuna de péptido de survivina |
| EP1934250A2 (en) * | 2005-09-09 | 2008-06-25 | Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | Methods and compositions for inhibiting cell death or enhancing cell proliferation |
| EP2361930A3 (en) | 2007-03-26 | 2011-10-26 | Dako Denmark A/S | Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases |
| EP2167537A2 (en) | 2007-07-03 | 2010-03-31 | Dako Denmark A/S | Compiled methods for analysing and sorting samples |
| EP2197908A2 (en) | 2007-09-27 | 2010-06-23 | Dako Denmark A/S | Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics |
| DK2254592T3 (da) | 2008-02-28 | 2019-09-09 | Dako Denmark As | MHC-multimerer til Borrelia-diagnostik og sygdom |
| WO2009106073A2 (en) * | 2008-02-28 | 2009-09-03 | Dako Denmark A/S | Mhc multimers in borrelia diagnostics and disease |
| ES2820873T3 (es) | 2008-05-16 | 2021-04-22 | Taiga Biotechnologies Inc | Anticuerpos y su procesos de preparación |
| EP2313516A4 (en) * | 2008-07-16 | 2012-04-04 | Burnham Inst Medical Research | COMPOSITIONS AND METHODS FOR MODULATING THE NOD LIKE RECEPTOR ACTIVITY AND THEIR USE |
| US10722562B2 (en) | 2008-07-23 | 2020-07-28 | Immudex Aps | Combinatorial analysis and repair |
| ES2681478T3 (es) | 2008-08-28 | 2018-09-13 | Taiga Biotechnologies, Inc. | Moduladores de MYC, métodos de uso de los mismos y métodos para identificar agentes que modulan MYC |
| GB0817244D0 (en) | 2008-09-20 | 2008-10-29 | Univ Cardiff | Use of a protein kinase inhibitor to detect immune cells, such as T cells |
| EP2337795A2 (en) * | 2008-10-01 | 2011-06-29 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
| WO2010037397A1 (en) * | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Mhc multimers in cmv immune monitoring |
| US11992518B2 (en) | 2008-10-02 | 2024-05-28 | Agilent Technologies, Inc. | Molecular vaccines for infectious disease |
| WO2010037402A1 (en) | 2008-10-02 | 2010-04-08 | Dako Denmark A/S | Molecular vaccines for infectious disease |
| JP2012505918A (ja) * | 2008-10-17 | 2012-03-08 | ユニバーシティー オブ マイアミ | 腫瘍ワクチン |
| US20120251509A1 (en) * | 2009-10-22 | 2012-10-04 | Waldman Scott A | Cell-based anti-cancer compositions and methods of making and using the same |
| CN105601727B (zh) * | 2010-03-11 | 2020-01-10 | 肿瘤疗法科学股份有限公司 | Hjurp肽及包含它们的疫苗 |
| AU2011293522B2 (en) * | 2010-08-24 | 2015-03-19 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines |
| SI3536334T1 (sl) | 2012-05-16 | 2021-11-30 | Stemline Therapeutics Inc. | Cepiva proti raku, ki ciljajo na rakave matične celice |
| CA3133302A1 (en) * | 2012-07-20 | 2014-01-23 | Taiga Biotechnologies, Inc. | Enhanced reconstitution and autoreconstitution of the hematopoietic compartment comprising a myc polypeptide |
| EP2961419A4 (en) * | 2013-02-26 | 2016-12-21 | Rongfu Wang | PHF20 AND JMJD3 COMPOSITIONS AND METHOD FOR USE IN CANCER IMMUNOTHERAPY |
| US20160010058A1 (en) * | 2013-03-01 | 2016-01-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv | Methods of producing enriched populations of tumor-reactive t cells from tumor |
| US9704181B2 (en) * | 2014-05-06 | 2017-07-11 | International Business Machines Corporation | Real-time social group based bidding system |
| AU2017367730A1 (en) | 2016-12-02 | 2019-06-06 | Taiga Biotechnologies, Inc. | Nanoparticle formulations |
| CR20210128A (es) | 2017-01-27 | 2021-04-26 | Immatics Biotechnologies Gmbh | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cancer (divisional exp. 2019-388) |
| US10738100B2 (en) | 2017-01-27 | 2020-08-11 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| TWI796314B (zh) * | 2017-01-27 | 2023-03-21 | 德商英麥提克生物技術股份有限公司 | 用於卵巢癌和其他癌症免疫治療的新型肽和肽組合物 |
| AU2019334437A1 (en) | 2018-09-04 | 2021-03-18 | Treos Bio Limited | Peptide vaccines |
| EP3898666A2 (en) | 2018-12-17 | 2021-10-27 | Immudex ApS | Panel comprising borrelia mhc multimers |
| AU2020272664A1 (en) | 2019-04-08 | 2021-11-04 | Taiga Biotechnologies, Inc. | Compositions and methods for the cry opreservation of immune cells |
| AU2020274117A1 (en) | 2019-05-14 | 2021-12-02 | Taiga Biotechnologies, Inc. | Compositions and methods for treating T cell exhaustion |
| CN113355432A (zh) * | 2021-05-12 | 2021-09-07 | 甘肃农业大学 | Bmf作为细胞凋亡标志物的应用 |
| WO2022245249A1 (ru) * | 2021-05-17 | 2022-11-24 | федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) | Пептидные соединения для индукции апоптоза в опухолевой клетке |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5554372A (en) | 1986-09-22 | 1996-09-10 | Emory University | Methods and vaccines comprising surface-active copolymers |
| US5342774A (en) | 1991-05-23 | 1994-08-30 | Ludwig Institute For Cancer Research | Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1 |
| FI950887A7 (fi) | 1992-08-31 | 1995-02-27 | Ludwig Inst For Cancer Res Ltd | MAGE-3-geenistä peräisin oleva ja HLA-A1-proteiinin tarjoama eristetty nonapeptidi ja sen käytöt |
| US5470955A (en) * | 1993-02-02 | 1995-11-28 | Dartmouth College | Antibodies which specifically bind mcl-1 polypeptide |
| US5646008A (en) * | 1993-06-22 | 1997-07-08 | The Regent Of The University Of Michigan | Vertebrate apoptosis gene: compositions and methods |
| US5700638A (en) * | 1993-08-26 | 1997-12-23 | Washington University | Cell death regulator |
| GB9320597D0 (en) | 1993-10-06 | 1993-11-24 | Proteus Molecular Design | Improvements in and realting to vaccines |
| US6096313A (en) | 1996-02-09 | 2000-08-01 | Ludwig Institute For Cancer Research | Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant |
| US5789201A (en) * | 1996-02-23 | 1998-08-04 | Cocensys, Inc. | Genes coding for bcl-y a bcl-2 homologue |
| AU736587B2 (en) | 1996-11-20 | 2001-08-02 | Yale University | Survivin, a protein that inhibits cellular apoptosis, and its modulation |
| WO1998058541A1 (en) * | 1997-06-24 | 1998-12-30 | Dana-Farber Cancer Institute, Inc. | Modulation of apoptosis |
| AU3471200A (en) * | 1999-11-16 | 2001-05-30 | Dartmouth College | Mcl-1 gene regulatory elements and a pro-apoptotic mcl-1 variant |
| AU2578401A (en) | 1999-12-14 | 2001-06-25 | Burnham Institute, The | Bcl-g polypeptides, encoding nucleic acids and methods of use |
| AU2001271426A1 (en) * | 2000-07-17 | 2002-01-30 | Washington University | Modulation of apoptosis |
| WO2002072627A2 (en) | 2001-03-09 | 2002-09-19 | Callistogen Ag | Induction of anti-tumor cytotoxic t-lymphocytes in humans using peptide epitopes found by computer based algorithms for vaccination |
| US7892559B2 (en) | 2002-01-30 | 2011-02-22 | Survac Aps | Survivin-derived peptides and use thereof |
| EP1618130B1 (en) | 2003-04-11 | 2013-03-27 | Survac ApS | Therapeutic cancer vaccine |
-
2004
- 2004-11-18 KR KR1020067012186A patent/KR101216655B1/ko not_active Expired - Lifetime
- 2004-11-18 CN CN2004800407050A patent/CN1921878B/zh not_active Expired - Lifetime
- 2004-11-18 WO PCT/DK2004/000799 patent/WO2005049073A2/en not_active Ceased
- 2004-11-18 US US10/580,016 patent/US7842294B2/en active Active
- 2004-11-18 DK DK04797460T patent/DK1691824T3/da active
- 2004-11-18 MX MXPA06005738A patent/MXPA06005738A/es active IP Right Grant
- 2004-11-18 CA CA2546794A patent/CA2546794C/en not_active Expired - Lifetime
- 2004-11-18 KR KR1020127016885A patent/KR101284237B1/ko not_active Expired - Lifetime
- 2004-11-18 ES ES04797460T patent/ES2323588T3/es not_active Expired - Lifetime
- 2004-11-18 AU AU2004290866A patent/AU2004290866B2/en not_active Expired
- 2004-11-18 JP JP2006540170A patent/JP4926714B2/ja not_active Expired - Lifetime
- 2004-11-18 EP EP04797460A patent/EP1691824B1/en not_active Expired - Lifetime
- 2004-11-18 DK DK09154734.9T patent/DK2087904T3/da active
- 2004-11-18 AT AT04797460T patent/ATE424842T1/de active
- 2004-11-18 RU RU2006121466/15A patent/RU2367468C2/ru active
- 2004-11-18 PT PT04797460T patent/PT1691824E/pt unknown
- 2004-11-18 DE DE602004019965T patent/DE602004019965D1/de not_active Expired - Lifetime
- 2004-11-18 PL PL04797460T patent/PL1691824T3/pl unknown
- 2004-11-18 ES ES09154734.9T patent/ES2436429T3/es not_active Expired - Lifetime
- 2004-11-18 EP EP09154734.9A patent/EP2087904B1/en not_active Expired - Lifetime
- 2004-11-18 ZA ZA200604866A patent/ZA200604866B/en unknown
- 2004-11-18 PL PL09154734T patent/PL2087904T3/pl unknown
-
2011
- 2011-09-12 JP JP2011198605A patent/JP5502823B2/ja not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007511547A5 (enExample) | ||
| RU2006121466A (ru) | БЕЛКИ, ОТНОСЯЩИЕСЯ К СЕМЕЙСТВУ Bcl-2, И ИХ ФРАГМЕНТЫ, И ИХ ПРИМЕНЕНИЕ У ПАЦИЕНТОВ СО ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛЬЮ | |
| TWI504407B (zh) | 癌疫苗組合物 | |
| Weber et al. | A phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete Freund's adjuvant in patients with resected high-risk melanoma | |
| CA2513104A1 (en) | Survivin-derived peptides and use thereof | |
| TWI285648B (en) | Compositions and methods for WT1 specific immunotherapy | |
| JP2003535824A (ja) | 抗原提示細胞におけるエピトープ同調 | |
| US20040009939A1 (en) | Methods of enhancing immune induction involving MDA-7 | |
| TW518340B (en) | Tumor antigen peptide derivative | |
| CN103547283A (zh) | 前列腺相关抗原分子来源的人类白细胞抗原结合肽及其使用方法 | |
| AU2008257791A1 (en) | P53 peptide vaccine | |
| JP2011506497A5 (enExample) | ||
| CN112867502A (zh) | Herv-k衍生抗原作为共有肿瘤抗原用于抗癌疫苗 | |
| JP5087925B2 (ja) | 新規癌抗原ペプチド及びその用途 | |
| WO2005068632A1 (ja) | ＨＬＡ−Ａ２４０２拘束性Ｅｐ−ＣＡＭ特異的ＣＴＬが認識するエピトープ・ペプチド及びその用途 | |
| WO2013175258A1 (en) | Novel melanoma antigen peptide and uses thereof | |
| HK1223971A1 (zh) | 肿瘤抗原肽 | |
| US9573975B2 (en) | Melanoma antigen peptide and uses thereof | |
| US10206990B2 (en) | Cytotoxic T lymphocyte inducing immunogens for prevention treatment and diagnosis of cancer | |
| CN108250266A (zh) | 一种hla-a11限制性gpc3源性多肽及包含它的疫苗 | |
| JPWO2003008450A1 (ja) | 腫瘍抗原 | |
| JP2004141154A (ja) | 腫瘍抗原 |